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Abstract
Background: Chronic Chagas Disease (CD) diagnosis is based on serological methods employing crude,
semipurified or recombinant antigens, which may result in low sensitivity or cross-reactivity. To reduce these
restrictions, we developed a strategy involving use of molecules containing repetitive fragments of Trypanosoma
cruzi conserved proteins. Diagnostic performance of IBMP-8.1 and IBMP-8.4 chimeric antigens (Molecular Biology
Institute of Paraná - IBMP in Portuguese acronym) was assessed to diagnose T. cruzi-infected and non-infected
immigrants living in Barcelona (Spain), a non-endemic setting for Chagas disease.
Methods: Reactivity of IBMP-8.1 and IBMP-8.4 was assessed using an in-house automated ELISA with 347 positive
and 331 negative individuals to Chagas disease. Antigenic cross-reactivity was measured with sera samples from
pregnant women with Toxoplasma gondii (n = 98) and Zika virus (n = 75) antibodies.
Results: The area under the curve values was 1 and 0.99 for the IBMP-8.1 and IBMP-8.4 proteins, respectively,
demonstrating excellent diagnostic accuracy. The reactivity index was higher for IBMP-8.1 than IBMP-8.4 in positive
samples and no significant difference in reactivity index was observed in negative samples. Sensitivity ranged from
99.4% for IBMP-8.1 to 99.1% for IBMP-8.4 and was not statistically different. Specificity for IBMP-8.1 reached 100 and
99.7% for IBMP-8.4, both nearly 100% accurate. No antigenic cross-reactivity was observed and reactivity index was
similar to that for negative Chagas disease individuals.
Conclusions: Our results showed an outstanding performance of IBMP-8.1 and IBMP-8.4 chimeric antigens by ELISA
and suggest both chimeric antigens could also be used for Chagas disease diagnosis in immigrants living in non-
endemic settings.
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Background
Chagas disease (CD) is a life-threatening infection caused by
hemoflagellate protozoa Trypanosoma cruzi, generating an
estimated of 14,000 deaths every year [1] and morbidity in
5.7 to 9.4 million people in the continental Western Hemi-
sphere [2, 3]. The epidemiological pattern of CD has under-
gone substantial changes in last decades as a consequence of
control campaigns in endemic countries, which have re-
duced vectorial and transfusional transmission [4]. Increas-
ing international migration flows and more affordable
traveling conditions from Latin America to non-endemic
areas have contributed to epidemiology changes [5, 6]. CD
is no longer limited exclusively to the impoverished rural re-
gions of Latin America; it is transformed into a global health
concern affecting people worldwide in both endemic and
non-endemic countries and placing 100 million people at
risk for acquiring the infection [7].
In Spain, there are more than 6 million immigrants,
and more than 2 million (38%) are coming from CD en-
demic Latin America countries [8], posing CD as a pub-
lic health challenge [9]. Indeed, Ecuador, Bolivia, and
Argentina are the predominant areas of origin [7]. The
diversity of the geographic areas leads to another chal-
lenge: the need for an accurate diagnostic test capable of
identifying individuals infected with different T. cruzi
strains. The high genetic variability of T. cruzi can be re-
sponsible for false negative results [10]. These false nega-
tive results could be avoided by using synthetic chimeric
antigens with repetitive fragments of antigenic T. cruzi
proteins for the detection of specific antibodies [11–14].
We performed ELISA [15, 16] and liquid microarray
[17] to assess the potential diagnostic of four chimeric
proteins, IBMP-8.1, IBMP-8.2, IBMP-8.3, and IBMP-8.4,
to identify T. cruzi-infected individuals from several Bra-
zilian endemic (Bahia, Goiás, Minas Gerais, and Pernam-
buco states; Brazil) and non-endemic settings (Paraná
state; Brazil). These chimeric antigens were composed of
immunodominant and conserved sequences, as de-
scribed previously [15]. We obtained high-performance
values and low cross-reactivity to Leishmania spp., a
pathogen showing relatively high antigenic similarity to
T. cruzi [15, 17]. Imprecision analyses showed that IBMP
chimeric antigens are highly reproducible and IBMP-8.1
and IBMP-8.4 presented the highest performance values
among the evaluated antigens. In this study, we endeav-
ored to conduct an evaluation of the diagnostic perform-
ance of IBMP-8.1 and IBMP-8.4 chimeric antigens
employing ELISA to diagnose T. cruzi-infected and
non-infected immigrants living in Barcelona (Spain), a
non-endemic setting for the CD.
Methods
We used the methodology previously described by San-
tos et al. [18] and Brito et al. [19].
Study samples
We employed anonymized human sera from individuals
diagnosed at the Laboratory Clínic l’Hospitalet-Labora-
tori Clínic Territorial Metropolitana Sur, Catalan Insti-
tute of Health (Barcelona-Spain). The minimum sample
with a 95% confidence interval, an absolute expected
error of 1.1% and sensitivity of 99% was 315 sera from
non-infected and 315 from T. cruzi-infected individuals.
We included sera from 331 non-infected and 347 T. cru-
zi-infected Latin American individuals living in Barce-
lona (Fig. 1). The sample selection was based on
non-reactivity and reactivity by two serological assays:
ORTHO® T. cruzi ELISA Test System (Ortho Clinical
Diagnostics Inc., Raritan, USA), which employs T. cruzi
whole cell lysate antigen; and Bioelisa CHAGAS (Biokit
S.A., Barcelona, Spain) or BIO-FLASH® Chagas (auto-
mated chemiluminescent assay; Biokit S.A., Barcelona,
Spain), the two latter composed by recombinant T. cruzi
antigens. Samples with repeatedly discrepant results be-
tween both tests or inconclusive in one of them (or in gray
zone) were defined as serodiscordant. Each sample was
given an identifier code in the laboratory to ensure a
blinded analysis. Antigenic cross-reactivity was assessed
with sera samples from Latin American pregnant women
with Toxoplasma gondii (n = 98) and Zika virus (ZIKV)
antibodies (n = 75). Pregnant women sera samples
were employed in this study due to the availability of
the biological material in Laboratory Clínic l’Hospita-
let-Laboratori Clínic Territorial Metropolitana Sur
serum bank. Study participants were mostly from
Bolivia (97.3%), but there were individuals from other
CD endemic countries (Fig. 1).
Recombinant antigens
Proteins were expressed in Escherichia coli Bl21 star DE3
and purified from the soluble fraction of the total extract
of bacterial lysate. Both IBMP-8.1 and IBMP-8.4 antigens
were purified by IMAC resin first, and the best fractions
dialyzed for buffer exchange and salt reduction before fol-
lowing a second liquid chromatography step. The second
purification was conducted on ionic exchange and heparin
columns, respectively. Plasmidial construct has already
been described in Santos et al. [18].
Immunoassays
Assays were conducted according to previous reports
[14, 16]. Briefly, polystyrene “Maxisorp” 96-well micro-
plates (Nunc, Roskilde, Denmark) were coated with 25.0
ng of IBMP-8.1 and IBMP-8.4 per well diluted in coating
buffer (0.05M carbonate-bicarbonate, pH 9.6). Micro-
plates were blocked with Well Champion reagent
(Kem-En-Tec, Taastrup, Denmark) according to the man-
ufacturer’s instructions. Serum samples were diluted in
0.05M phosphate-buffered saline (pH 7.2)-0.5% Tween 20
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(PBS-T), and 100 μl was added to each well. After 60min
of incubation at 37 °C, microplates were washed in PBS-T
to remove unbound antibodies. HRP conjugated goat
anti-human IgG (Bio-Manguinhos, FIOCRUZ, Rio de
Janeiro, Brazil) was diluted 1:40,000 in PBS-T, and 100 μl
were then added to each well, and the microplates were
incubated for 30min at 37 °C. Wells were washed five
times and the immune complexes were revealed by the
addition of 100 μl TBM substrate (tetramethyl-benzidine;
Kem-En-Tec, Taastrup, Denmark). After a new cycle of in-
cubation (10min at RT in the dark), the reaction was
stopped by adding 50 μl 5 N H2SO4, and the absorbance
was measured at 450 nm. The protocols were automatized
and the runs carried out in an automated microplate
immunoanalyser (BEST 2000®, Biokit, Werfen Group Bar-
celona, Spain). The blank readings (buffer dilution) was
subtracted from all other values.
Statistical analysis
Data were coded and entered using computer graphic
software (GraphPad Software Inc., La Jolla, CA, USA).
Descriptive data were presented in the form of geomet-
ric means ± standard deviation. Shapiro-Wilk test,
followed by Student’s t-test, was used to test data nor-
mality. When assumed homogeneity was not confirmed,
Wilcoxon’s signed rank test was adopted. Cut-off values
were determined under the receiver operating character-
istic curve (ROC) analyzing the whole serum panel. For
data normalization, all results were expressed by plotting
values in an indexed format, calculated as the ratio be-
tween a given sample’s optical density (OD) and the
cut-off OD values respective to each assay. Under this
index, referred to as a reactivity index (RI), all results
≥1.00 were considered positive. When a sample’s RI value
was 1.0 ± 10%, the result was considered as indeterminate
(i.e., in the grey zone), and these samples were deemed in-
conclusive. The test performances were computed using a
dichotomous approach and compared regarding sensitiv-
ity, specificity, and accuracy [20]. Confidence interval was
set to 95% and p < 0.05 was considered as statistically sig-
nificant. A study workflow (Fig. 2) is provided according
to the STARD guidelines [21]. Digital map (Fig. 1) was ac-
quired from the Brazilian Institute of Geography and Sta-
tistics (IBGE) cartographic database in shapefile (.shp),
which were formatted and analyzed using TerraView ver-
sion 4.2, public-access software provided by the National
Institute for Space Research from Brazil (www.dpi.inpe.br/
terraview).
Results
Diagnostic performance
The reactivity index and assay performance parameters
found for the IBMP-8.1 and IBMP-8.4 chimeric antigens
are illustrated in Fig. 3. Based on 678 samples from
non-infected and T. cruzi-infected individuals, the AUC
(area under the curve) values were 1.000 and 0.9998 for
IBMP-8.1 and IBMP-8.4 proteins, respectively, demon-
strating excellent overall diagnostic accuracy. The
IBMP-8.1 chimera yielded the highest diagnostic accur-
acy among T. cruzi-infected individuals, and no signifi-
cant difference was observed between chimeric antigens
in non-infected individuals. Sensitivity was 99.4% for
IBMP-8.1 and 99.1% for IBMP-8.4. Only one positive
sample was simultaneously false negative when assayed
by IBMP-8.1 and IBMP-8.4 chimeric antigens. Specificity
of IBMP-8.1 achieved 100 and 99.7% for IBMP-8.4. Both
proteins showed an accuracy of nearly 100%. No statisti-
cally significant differences in sensitivity or specificity
scores were found between the chimeric antigens. Using
RI values of 1.0 ± 0.10 as the grey zone inconclusive
interval, we observed two positive and one negative sam-
ple fell in the inconclusive space using IBMP-8.1 while
two positive samples to IBMP-8.4 presented similar be-
havior. Overall, the number of inconclusive results was
0.44% for IBMP-8.1 and 0.29% for IBMP-8.4 (Fig. 3). No
sample fell concomitantly inside the grey zone for
IBMP-8.1 and IBMP8.4 chimeric antigens.
Fig. 1 T. cruzi-positive and negative samples selected from Latin American immigrants living in Barcelona-Spain
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Fig. 2 Study workflow for testing IBMP T. cruzi chimeras. RI, reactivity index; ZIKV, Zika virus
Fig. 3 Reactivity index (RI) was obtained with serum from non-infected and T. cruzi-infected immigrants living in Barcelona-Spain. The cut-off
value is RI = 1.0 and the grey zone is RI = 1.0 ± 0.10. Lines and whiskers represent geometric means (± 95% CI). AUC, area under curve; GZ, grey
zone; Sen, sensitivity; Spe, specificity; Acc; accuracy
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Antigenic cross-reactivity
The RI values for sampled with T. gondii and ZIKV anti-
bodies were identical to that found for non-infected in-
dividuals, indicating extremely low reactivity. No
false-positive or inconclusive samples were found with
IBMP chimeric antigens (Fig. 4).
Discussion
Diagnosis of chronic CD is not a simple task due to the
high genetic diversity of T. cruzi, which might lead to mis-
diagnosis [22]. In fact, T. cruzi parasite has remarkable
genetic heterogeneity, it is classified into seven evolution-
ary genetic groups or discrete typing units (DTUs) termed
TcI-TcVI and TcBat, with sub-classifications for regional
strains [22–24]. Regional differences in sensitivity of sero-
logical tests had been reported, leading to negative CD
diagnosis, mostly in non-endemic countries that receive
immigrants from several endemic areas [25–28]. There-
fore, a serological test should be able to diagnose CD re-
gardless of the T. cruzi antigenic heterogeneity. The main
benefit in the use of chimeric antigens as antigenic matrix
is the increased repertoire of epitopes in comparison to
non-chimeric recombinant antigens, reducing the number
of false negative results. In previous studies, our group an-
alyzed the IBMP performance to diagnose T. cruzi-in-
fected individuals in several endemic and non-endemic
geographical areas from Brazil [14, 15], a country where
TcII is predominant [10]. Here, we used two chimeric an-
tigens to capture specific anti-T. cruzi antibodies in the
sera of Latin American immigrants living in Barcelona/
Spain, a non-endemic setting for CD. The majority of
CD-positive samples were collected from Bolivian immi-
grants, where TcV is the most common DTU found in
Bolivia [10] and predominates in Bolivian immigrants liv-
ing in Barcelona [29]. Based on the result from previous
studies, we suggest that IBMP-8.1 and IBMP-8.4 antigens
are able to diagnose chronic Chagas disease in areas with
predominance of TcII and TcV genetic groups.
The assays exhibited high diagnostic accuracy values
as demonstrated by AUC (nearly 100%), indicating a
substantial discriminative power between negative and
chronic CD-positive samples. Similar results were previ-
ously found in samples from several Brazilian settings
both by ELISA (AUC > 99.7%) [14] and liquid microarray
(AUC > 99.1%) [17]. Moreover, the reactivity index from
IBMP-8.1 and IBMP-8.4 chimeric antigens, achieved
from immigrants living in a non-endemic setting with
CD, was higher than those previously obtained for Bra-
zilian samples [14]. It is interesting to note that no dif-
ferences were observed concerning negative samples.
Further studies need to evaluate the performance of the
chimeric antigens in settings where other DTUs are pre-
dominant, i.e., Argentina, Mexico and Costa Rica.
The present study showed high sensitivity and specifi-
city for both IBMP-8.1 and IBMP-8.4, similar to those
found previously using Brazilian samples [14, 15]. Also,
the chimeric antigens were found to be nearly 100% ac-
curate, suggesting that the number of misdiagnoses was
negligible. In fact, only two and three CD-positive sam-
ples were misclassified when assayed with IBMP-8.1 and
IBMP-8.4, respectively. In previous studies we evaluated
the increase of sensitivity values and the RI signal using
a multiplex methodology [17] or the equimolar mixture
of the antigens [15], however no gains of were achieved.
Hence, we believe that the lack of reactivity from these
samples could be due to host immunological reasons or
low levels of antibodies on the sera. In CD-negative sam-
ples, only one sample was classified as false-positive by
IBMP-8.4 antigen. Although this sample presented low
signal to IBMP-8.4 (1.28), it was classified as negative
when assayed by commercial tests (RI < 0.25) and by the
IBMP-8.1 chimera (0.22).
Fig. 4 Analysis of the cross-reactivity of the IBMP-8.1 and IBMP-8.4 chimeras to sera with Toxoplasma gondii antibodies (n = 98) and Zika virus
antibodies (n = 75). The cut-off value is 1.0 and the grey zone is RI = 1.0 ± 0.10. Lines and whiskers represent geometric means (± 95% CI). GZ,
grey zone; RI, reactivity index; ZIKV, Zika virus
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No cross-reactivity of IBMP chimeric antigens against
antibodies of T. gondii and ZIKV was observed. Indeed,
previous studies have shown extremely low reactivity of
IBMP chimeric antigens for several infectious diseases,
even for Leishmania spp. [15, 17], a pathogen phylogen-
etically similar to T. cruzi. T. gondii and ZIKV positive
samples were used in this study due to serum bank avail-
ability and because these infectious diseases did not
assay before using IBMP proteins.
Conclusion
Our results showed a remarkable performance of
IBMP-8.1 and IBMP-8.4 chimeric antigens by ELISA
and suggest both antigens could also be used for CD
diagnosis in immigrants living in non-endemic settings.
The high accuracy of IBMP-8.1 and IBMP-8.4 chimeric
antigens suggests that they are useful for CD diagnosis
in individuals infected with other DTUs.
Abbreviations
Acc: Accuracy; AUC: Area under the curve; CD: Chagas disease; DTU: Discrete
typing unit; GZ: Grey zone; HRP: Horseradish peroxidase; IBMP: Molecular
Biology Institute of Paraná (IBMP in Portuguese acronym); OD: Optical
density; PBS: Phosphate-buffered saline; PBS-T: Phosphate-buffered saline-
0.5% Tween 20; RI: Reactivity index; ROC: Receiving operator curve;
Sen: Sensitivity; Spe: Specificity; STARD: Standards for reporting of diagnostic
accuracy studies; T. cruzi: Trypanosoma cruzi; T. gondii: Toxoplasma gondii;
TBM: Tetramethyl-benzidine; ZIKV: Zika virus
Acknowledgements
The authors would like to address a special thanks to Ignacio Martínez
(Departmento de Immunologia, Instituto de Investigaciones Biomedicas,
Universidad Nacional Autonoma de Mexico) and Jesus Almeda (Unitat de
Suport a la Recerca, Direcció d’Atenció Primària Costa de Ponent-IDIAP J Gol)
for their critical review. We also thank the staff at the Laboratori Clínic Hospitalet
(Laboratori Clínic Territorial Metropolitana Sud, Catalan Institute of Health,
Barcelona/Spain), especially Elisabeth Castro, as well as Montse Graells
and Cristina Fernández for help with sample collection and laboratory analysis.
Availability of the data and materials
The datasets used and analyzed during the current study are available from
the corresponding author on reasonable request.
Funding
This research project was funded by a Gonçalo Moniz Institute, Oswaldo
Cruz Foundation (Fiocruz/BA). The funder was not involved in the design of
the study, in the collection, analysis and interpretation of the data, or in
writing the manuscript.
Authors’ contributions
FLNS and ED were involved in the design and operational management of
the study. FLNS and WVS were the lead study statistician. ED and RPDR were
principal investigators in this study. All authors (ED, RPDR, BE, IU, NITZ, ES,
ZM, PAFC, WVS, EDS, YMG, and FLNS) contributed to the interpretation of
the data, contributed to this publication and approved the final manuscript
for submission. All authors (ED, RPDR, BE, IU, NITZ, ES, ZM, PAFC, WVS, EDS,
YMG, and FLNS) had access to the study data and are responsible for the
veracity and completeness of the data reported.
Author information
FLNS is investigator in public health at Gonçalo Moniz Institute, Oswaldo
Cruz Foundation (Fiocruz), Brazil.
Ethics approval and consent to participate
Ethical permission was sought and granted by Clinical Research Ethics
Committee of Bellvitge University Hospital (Barcelona, Spain; IRB OHRP:
IRB00005523), and was carried out in accordance with the guidelines of the
Helsinki Declaration. With the purpose of protecting the patient’s private
information, the Clinical Research Ethics Committee of Bellvitge University
Hospital approved that the samples were anonymized so that the investigators
do not have access to patient’s private information, therefore, avoiding the
requirement of verbal or written consent. This manuscript has also been revised
for its publication by the Clinical Research Ethics Committee of Bellvitge
University Hospital.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Laboratori Clínic Territorial Metropolitana Sud, Catalan Institute of Health,
Barcelona, Catalonia, Spain. 2Faculty of Technology and Sciences of Bahia,
Salvador, Bahia, Brazil. 3Instituto de Investigaciones Biomédicas,
Departamento de Inmunología, Universidad Nacional Autónoma de México,
Ciudad de México, Mexico. 4Carlos Chagas Institute, Oswaldo Cruz
Foundation, Curitiba, Paraná, Brazil. 5Microbiology Department, Vall d’Hebron
University Hospital, PROSICS, Barcelona, Catalonia, Spain. 6Molecular Biology
Institute of Paraná, Curitiba, Paraná, Brazil. 7Aggeu Magalhães Institute,
Oswaldo Cruz Foundation, Recife, Pernambuco, Brazil. 8Immunobiological
Technology Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
9Gonçalo Moniz Institute, Oswaldo Cruz Foundation, Salvador, Bahia, Brazil.
Received: 24 September 2018 Accepted: 4 March 2019
References
1. Hotez PJ, Dumonteil E, Woc-Colburn L, Serpa JA, Bezek S, Edwards MS, et al.
Chagas disease: “the new HIV/AIDS of the Americas”. PLoS Negl Trop Dis.
2012;6(5):e1498.
2. World Health Organization. Chagas disease in Latin America: an
epidemiological update based on 2010 estimates. Wkly Epidemiol Rec.
2015;90(6):33–43.
3. Global Burden of Disease Study 2013 Collaborators, Collaborators GB of DS
2013. Global, regional, and national incidence, prevalence, and years lived
with disability for 301 acute and chronic diseases and injuries in 188
countries, 1990-2013: a systematic analysis for the global burden of disease
study 2013. Lancet. 2015;386(9995):743–800.
4. Soriano Arandes A, Muñoz Gutierrez J, Vergés Navarro M, Castells
Doménech C, Portús Vinyeta M, Gascón Brustenga J. Prevalence of Chagas
disease in the Latin American immigrant population in a primary health
Centre in Barcelona (Spain). Acta Trop. 2009;112(2):228–30.
5. Angheben A, Boix L, Buonfrate D, Gobbi F, Bisoffi Z, Pupella S, et al. Chagas
disease and transfusion medicine: a perspective from non-endemic
countries. Blood Transfus. 2015;13(4$):540–50.
6. Pane S, Giancola ML, Piselli P, Corpolongo A, Repetto E, Bellagamba R, et al.
Serological evaluation for Chagas disease in migrants from Latin American
countries resident in Rome, Italy. BMC Infect Dis. 2018;18(1):212.
7. Strasen J, Williams T, Ertl G, Zoller T, Stich A, Ritter O. Epidemiology of
Chagas disease in Europe: many calculations, little knowledge. Clin Res
Cardiol. 2014;103(1):1–10.
8. Eurostat. Total number of long-term immigrants arriving into the reporting
country during the reference year. Available from: http://ec.europa.eu/
eurostat/tgm/table.do?tab=table&init=1&plugin=1&pcode=
tps00176&language=fr. Accessed 16 Oct 2017.
9. Instituto Nacional de Estadística. Población residente por fecha, sexo, edad,
nacionalidad (agrupación de países) y lugar de nacimiento (agrupación de
países). Available from: http://www.ine.es/jaxiPx/tabla.do?type=pcaxis&path=/
t20/p321/serie/2001/l0/&file=01005.px&L=1. Accessed 18 Oct 2017.
10. Zingales B. Trypanosoma cruzi genetic diversity: something new for
something known about Chagas disease manifestations, serodiagnosis and
drug sensitivity. Acta Trop. 2018;184:38–52.
Dopico et al. BMC Infectious Diseases          (2019) 19:251 Page 6 of 7
11. Camussone C, Gonzalez V, Belluzo MS, Pujato N, Ribone ME, Lagier CM,
et al. Comparison of recombinant Trypanosoma cruzi peptide mixtures
versus multiepitope chimeric proteins as sensitizing antigens for
immunodiagnosis. Clin Vaccine Immunol. 2009;16(6):899–905.
12. Hernández P, Heimann M, Riera C, Solano M, Santalla J, Luquetti AO, et al.
Highly effective serodiagnosis for Chagas’ disease. Clin Vaccine Immunol.
2010;17(10):1598–604.
13. Houghton RL, Benson DR, Reynolds LD, McNeill PD, Sleath PR, Lodes MJ,
et al. A multi-epitope synthetic peptide and recombinant protein for the
detection of antibodies to Trypanosoma cruzi in radioimmunoprecipitation-
confirmed and consensus-positive sera. J Infect Dis. 1999;179(5):1226–34.
14. Mucci J, Carmona SJ, Volcovich R, Altcheh J, Bracamonte E, Marco JD, et al.
Next-generation ELISA diagnostic assay for Chagas disease based on the
combination of short peptidic epitopes. PLoS Negl Trop Dis. 2017;11(10):
e0005972.
15. Santos FL, Celedon PA, Zanchin NI, Souza WV, Silva ED, Foti L, et al.
Accuracy of chimeric proteins in the serological diagnosis of chronic
Chagas disease - a phase II study. PLoS Negl Trop Dis. 2017;11(3):e0005433.
16. Santos FL, Campos AC, Amorim LD, Silva ED, Zanchin NI, Celedon PA, et al.
Highly accurate chimeric proteins for the serological diagnosis of chronic
Chagas disease: a latent class analysis. Am J Trop Med Hyg. 2018;99(5):1174–9.
17. Santos FL, Celedon PA, Zanchin NI, Leitolis A, Crestani S, Foti L, et al.
Performance assessment of a Trypanosoma cruzi chimeric antigen in
multiplex liquid microarray assays. J Clin Microbiol. 2017;55(10):2934–45.
18. Santos FL, Celedon PA, Zanchin NI, Brasil TA, Foti L, Souza WV, et al.
Performance assessment of four chimeric Trypanosoma cruzi antigens based
on antigen-antibody detection for diagnosis of chronic Chagas disease.
PLoS One. 2016;11(8):e0161100.
19. Brito VS, Santos FL, Gonçalves NL, Araujo TH, Nascimento DS, Pereira FM,
et al. Performance of commercially available serological screening tests for
human T-cell lymphotropic virus infection in Brazil. J Clin Microbiol. 2018;
56(12):e00961–18.
20. Leeflang MM, Allerberger F. How to: evaluate a diagnostic test. Clin
Microbiol Infect. 2019;25(1):54–9.
21. Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA, Hooft L, et al.
STARD 2015 guidelines for reporting diagnostic accuracy studies:
explanation and elaboration. BMJ Open. 2016;6(11):e012799.
22. Tibayrenc M, Ayala FJ. Towards a population genetics of microorganisms:
the clonal theory of parasitic protozoa. Parasitol Today. 1991;7(9):228–32.
23. Zingales B, Andrade SG, Briones MR, Campbell DA, Chiari E, Fernandes O,
et al. A new consensus for Trypanosoma cruzi intraspecific nomenclature:
second revision meeting recommends TcI to TcVI. Mem Inst Oswaldo Cruz.
2009;104(7):1051–4.
24. Zingales B, Miles MA, Campbell DA, Tibayrenc M, Macedo AM, Teixeira MM,
et al. The revised Trypanosoma cruzi subspecific nomenclature: rationale,
epidemiological relevance and research applications. Infect Genet Evol.
2012;12(2):240–53.
25. Umezawa ES, Bastos SF, Camargo ME, Yamauchi LM, Santos MR, Gonzalez A,
et al. Evaluation of recombinant antigens for serodiagnosis of Chagas’
disease in south and Central America. J Clin Microbiol. 1999;37(5):1554–60.
26. Umezawa ES, Bastos SF, Coura JR, Levin MJ, Gonzalez A, Rangel-Aldao R, et
al. An improved serodiagnostic test for Chagas’ disease employing a
mixture of Trypanosoma cruzi recombinant antigens. Transfusion. 2003;43(1):
91–7.
27. Verani JR, Seitz A, Gilman RH, LaFuente C, Galdos-Cardenas G, Kawai V, et al.
Geographic variation in the sensitivity of recombinant antigen-based rapid
tests for chronic Trypanosoma cruzi infection. Am J Trop Med Hyg. 2009;
80(3):410–5.
28. Martin DL, Marks M, Galdos-Cardenas G, Gilman RH, Goodhew B, Ferrufino L,
et al. Regional variation in the correlation of antibody and T-cell responses
to Trypanosoma cruzi. Am J Trop Med Hyg. 2014;90(6):1074–81.
29. Abras A, Gállego M, Muñoz C, Juiz NA, Ramírez JC, Cura CI, et al.
Identification of Trypanosoma cruzi discrete typing units (DTUs) in Latin-
American migrants in Barcelona (Spain). Parasitol Int. 2017;66(2):83–8.
Dopico et al. BMC Infectious Diseases          (2019) 19:251 Page 7 of 7
